FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380681008> ?p ?o ?g. }

• W4380681008 abstract "Abstract The SARS-CoV-2 Omicron variant evades most currently approved neutralizing antibodies (nAbs) and caused drastic decrease of plasma neutralizing activity elicited by vaccination or prior infection, urging the need for the development of pan-variant antivirals. Breakthrough infection induces a hybrid immunological response with potentially broad, potent and durable protection against variants, therefore, convalescent plasma from breakthrough infection may provide a broadened repertoire for identifying elite nAbs. We performed single-cell RNA sequencing (scRNA-seq) and BCR sequencing (scBCR-seq) of B cells from BA.1 breakthrough-infected patients who received 2 or 3 previous doses of inactivated vaccine. Elite nAbs, mainly derived from the IGHV2–5 and IGHV3-66/53 germlines, showed potent neutralizing activity across Wuhan-Hu-1, Delta, Omicron sublineages BA.1 and BA.2 at picomolar NT 50 values. Cryo-EM analysis revealed diverse modes of spike recognition and guides the design of cocktail therapy. A single injection of paired antibodies cocktail provided potent protection in the K18-hACE2 transgenic female mouse model of SARS-CoV-2 infection." @default.
• W4380681008 created "2023-06-15" @default.
• W4380681008 creator A5001727480 @default.
• W4380681008 creator A5002388955 @default.
• W4380681008 creator A5002900862 @default.
• W4380681008 creator A5004056407 @default.
• W4380681008 creator A5006046188 @default.
• W4380681008 creator A5007724104 @default.
• W4380681008 creator A5008000502 @default.
• W4380681008 creator A5010053857 @default.
• W4380681008 creator A5013550923 @default.
• W4380681008 creator A5016841237 @default.
• W4380681008 creator A5020236787 @default.
• W4380681008 creator A5020579375 @default.
• W4380681008 creator A5022169204 @default.
• W4380681008 creator A5026388330 @default.
• W4380681008 creator A5026530336 @default.
• W4380681008 creator A5028006416 @default.
• W4380681008 creator A5029030051 @default.
• W4380681008 creator A5029164482 @default.
• W4380681008 creator A5030126374 @default.
• W4380681008 creator A5030683638 @default.
• W4380681008 creator A5036564567 @default.
• W4380681008 creator A5040444638 @default.
• W4380681008 creator A5041339619 @default.
• W4380681008 creator A5045534627 @default.
• W4380681008 creator A5048376599 @default.
• W4380681008 creator A5052017382 @default.
• W4380681008 creator A5056028884 @default.
• W4380681008 creator A5062961921 @default.
• W4380681008 creator A5071009209 @default.
• W4380681008 creator A5072253883 @default.
• W4380681008 creator A5075432747 @default.
• W4380681008 creator A5076819684 @default.
• W4380681008 creator A5085043657 @default.
• W4380681008 creator A5087268377 @default.
• W4380681008 creator A5087842032 @default.
• W4380681008 creator A5087947210 @default.
• W4380681008 creator A5090366405 @default.
• W4380681008 creator A5090454429 @default.
• W4380681008 creator A5090969106 @default.
• W4380681008 date "2023-06-15" @default.
• W4380681008 modified "2023-10-16" @default.
• W4380681008 title "Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection" @default.
• W4380681008 cites W2029525307 @default.
• W4380681008 cites W2103503400 @default.
• W4380681008 cites W2124026197 @default.
• W4380681008 cites W2132629607 @default.
• W4380681008 cites W2142161929 @default.
• W4380681008 cites W2154714625 @default.
• W4380681008 cites W2180229411 @default.
• W4380681008 cites W2185265351 @default.
• W4380681008 cites W2411563451 @default.
• W4380681008 cites W2587625522 @default.
• W4380681008 cites W2593511418 @default.
• W4380681008 cites W2800392236 @default.
• W4380681008 cites W2817838603 @default.
• W4380681008 cites W3024602798 @default.
• W4380681008 cites W3025987322 @default.
• W4380681008 cites W3026265675 @default.
• W4380681008 cites W3032255042 @default.
• W4380681008 cites W3034548712 @default.
• W4380681008 cites W3042323010 @default.
• W4380681008 cites W3048714202 @default.
• W4380681008 cites W3128961456 @default.
• W4380681008 cites W3143907823 @default.
• W4380681008 cites W3159233173 @default.
• W4380681008 cites W3159257193 @default.
• W4380681008 cites W3160207037 @default.
• W4380681008 cites W3164692211 @default.
• W4380681008 cites W3164769914 @default.
• W4380681008 cites W3170333570 @default.
• W4380681008 cites W3183072827 @default.
• W4380681008 cites W4205497912 @default.
• W4380681008 cites W4205660968 @default.
• W4380681008 cites W4207077800 @default.
• W4380681008 cites W4210261834 @default.
• W4380681008 cites W4213257347 @default.
• W4380681008 cites W4214532832 @default.
• W4380681008 cites W4214735462 @default.
• W4380681008 cites W4220673385 @default.
• W4380681008 cites W4221084154 @default.
• W4380681008 cites W4225647476 @default.
• W4380681008 cites W4281754639 @default.
• W4380681008 cites W4281873659 @default.
• W4380681008 cites W4282975248 @default.
• W4380681008 cites W4283026725 @default.
• W4380681008 cites W4283646162 @default.
• W4380681008 cites W4283833246 @default.
• W4380681008 cites W4290085573 @default.
• W4380681008 cites W4291020805 @default.
• W4380681008 cites W4295079698 @default.
• W4380681008 cites W4297537362 @default.
• W4380681008 cites W4307445711 @default.
• W4380681008 cites W4311359167 @default.
• W4380681008 cites W4312019047 @default.
• W4380681008 cites W4312210144 @default.
• W4380681008 cites W4313488719 @default.
• W4380681008 doi "https://doi.org/10.1038/s41467-023-39267-x" @default.
• W4380681008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37322000" @default.

• next